The SpyGlass Pharma clinical study is evaluating an investigational intraocular lens (IOL) designed for patients who need cataract surgery and also have glaucoma or ocular hypertension. This uniquely designed, single-piece IOL features drug-eluting pads that slowly release bimatoprost—an FDA-approved medication used by millions—to lower eye pressure daily for up to three years. By participating, patients receive eye examinations and follow-up care for three years, along with reimbursement for their time and travel, while helping researchers study this new platform for long-term, internal drug delivery.
